Pricing Log in Create free account
Friday 6 November 2026 Export ORKA’s income statement to Excel — free account

Oruka Therapeutics, Inc.

ORKA Healthcare Biotechnology

EPS
−19.6%
Free cash flow
−43.0%

Quarter to June 2026, against a year earlier

102.68 6.66 +6.94%
Market cap
$6.4B
P/E
0.0×
Fwd P/E
—
Dividend yield
0.00%
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Oruka Therapeutics, Inc. 8-K filed Sep 5, 2024

Period ended Aug 29, 2024 · Filed · accepted 5:18 PM ET · Document on sec.gov · Filing index

1.01 Entry into a material definitive agreement; 2.01 Completion of an acquisition or disposition; 2.02 Results of operations and financial condition; 3.03 Material modification of shareholders' rights; 4.01 Change in the certifying accountant; 5.01 Change in control; 5.02 Departure or appointment of directors or officers; 5.03 Amendments to the articles or bylaws; change in fiscal year; 5.05 Amendments to the code of ethics; 5.06 Change in shell company status; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release